-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Adarx Pharmaceuticals, Lowers Price Target to $36

Benzinga·11/19/2026 19:12:20
Listen to the news
JP Morgan analyst Tessa Romero maintains Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight and lowers the price target from $38 to $36.